|  | HIV Meds Quarterly | | Source: AETC National Resource Center and UCSF Center for HIV Information
Description: HIV Meds Quarterly provides brief updates and analysis of new findings related to common therapies used by HIV clinicians.  | Interactions:
Rosuvastatin Levels Increased by Ritonavir-Boosted Darunavir; Fosamprenavir and Posaconazole
| | | Research Briefs: Recent Advances in Once-Daily Therapies and Fixed-Dose Combination Regimens:
Rilpivirine (TMC278) in Initial Therapy; S/GSK 572 in Initial Therapy: Interim Results of SPRING-1; Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir ("Quad" Pill) in Initial Therapy; Novel Pharmacokinetic Booster Cobicistat (GS-9350)
| | | Fast Takes:
Maraviroc in patients with kidney disease; Didanosine and noncirrhotic portal hypertension
| | | Reference Table:
Updates to the Database of ARV Drug Interactions
| |
| Interactions:
Efavirenz and Levonorgestrel; Lopinavir/ritonavir and Buprenorphine
| | | Research Brief:
Vicriviroc in Treatment-Experienced Patients
| | | Fast Takes:
Ritonavir tablet formulation; Maraviroc approved for initial therapy; Saquinavir/ritonavir and possible risk of abnormal heart rhythms
| | | Reference Table:
Updates to the Database of ARV Drug Interactions
| |
| Research Briefs:
Kaletra Dosage Adjustment for Patients on Efavirenz or Nevirapine; Once-Daily Raltegravir; Atazanavir and Lopinavir/Ritonavir in Hemodialysis
| | | Reference Table:
Updates to the Database of ARV Drug Interactions
| |
| Research Briefs:
Regimen Simplification: Atazanavir vs Atazanavir/Ritonavir; Atazanavir/Ritonavir in Pregnancy; Investigational Integrase Inhibitor Shows Potent Activity in Early Studies
| | | Reference Table:
Updates to the Database of ARV Drug Interactions
| | | Fast Takes:
Raltegravir approved for initial therapy
| |
| Research Briefs:
Rosiglitazone and Heart Disease; Antipsychotics and Sudden Cardiac Death; New Pharmacokinetic Booster on the Horizon; Interleukin-2: No Clinical Benefit; Raltegravir Substitution for Lopinavir/Ritonavir (SWITCHMRK Study); Abacavir and Myocardial Infarction Risk: Additional Data
| | | Reference Table:
Updates to the Database of ARV Drug Interactions
| | | Fast Takes:
Darunavir: Traditional approval
| | | Guidelines:
New Guidelines: Adult OI prevention and treatment; Updated: Pediatric ARV guidelines; Updated: Perinatal guidelines
| |
| Research Briefs:
Darunavir Approved for Use with Boosted Ritonavir as "Preferred" PI, Pediatric Dosing
| | | Fast Takes:
Recent news about maraviroc, abacavir: pediatric formulation, and abacavir/lamivudine: DHHS recommendations
| |
| Research Briefs:
Pregabalin for Neuropathic Pain: Not More Effective Than Placebo; Abacavir/Lamivudine: Higher Rates of Virologic Failure in ARV-Naive Patients with HIV RNA ≥100,000 copies/mL compared with Tenofovir/Emtricitabine; Abacavir and Risk of Myocardial Infarction: The SMART Study
| | | Interactions:
Atazanavir: Interactions with Efavirenz, Nevirapine, and Oral Hormonal Contraceptives
| | | Fast Takes:
Recent news about ritonavir, darunavir, atazanavir + ritonavir, tenofovir, zidovudine, and didanosine
| |
| Research Briefs:
Abacavir and Didanosine Associated with Increased Risk of Myocardial Infarction; Testing for Chemokine Coreceptor Tropism
| | | Interactions:
Rosuvastatin with Lopinavir/Ritonavir and Tipranavir; Rifampin and "Super-Boosted" Protease Inhibitors
| | | Fast Takes:
Recent news about nelfinavir, tipranavir, lopinavir/ritonavir, and nevirapine
| |
| Research Briefs:
Atazanavir Efficacy Data and Changes in Dosage Recommendations; Raltegravir Substitution for Enfuvirtide; HLA-B*5701 Screening
| | | Reference Table:
Etravirine-ARV Interactions
| | | Fast Takes:
Recent news about darunavir, lamivudine, lopinavir/ritonavir and amprenavir
| |
|
|
